Biotech Values

[DewDiligence]

MGNX -16%/AH on weak OS data in phase-3 SOPHIA study:

https://www.globenewswire.com/news-release/2019/10/22/1933665/0/en/MacroGenics-Announces-Second-Interim-Overall-Survival-Data-from-Phase-3-SOPHIA-Study-of-Margetuximab-in-Patients-with-HER2-Positive-Metastatic-Breast-Cancer.html

This study met its primary endpoint of PFS, as previously reported (#msg-146611035, #msg-149203996).